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2ABSTRACT22
23
Background: Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia caused by RMRP24
(RNA component of mitochondrial RNA processing endoribonuclease) gene mutations. Manifestations25
include short stature, variable immunodeficiency, anemia and increased risk of malignancies, all of which26
have been described also in telomere biology disorders. RMRP interacts with the telomerase reverse27
transcriptase (TERT) subunit, but the influence of RMRP mutations on telomere length is unknown. We28
measured relative telomere length (RTL) in patients with CHH, their first-degree relatives and healthy29
controls, and correlated RTL with clinical and laboratory features.30
Methods: The study cohort included 48 CHH patients with homozygous (n=36) or compound heterozygous31
RMRP mutations (median age 38.2 years, range 6.0-70.8 years), 86 relatives (74 with a heterozygous RMRP32
mutation) and 94 unrelated healthy controls. We extracted DNA from peripheral blood, sequenced the RMRP33
gene and measured RTL by quantitative-PCR.34
Results: Compared with age- and sex-matched healthy controls, median RTL was significantly shorter in35
CHH patients (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10,36
p=0.224). RTL correlated significantly with age in RMRP mutation carriers (rho -0.482, p<0.001) and non-37
carriers (rho -0.498, p<0.001), but not in patients (rho -0.236, p=0.107). Especially children (<18 years) with38
CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008). In patients with CHH, RTL39
showed no correlation with genotype, clinical or laboratory characteristics.40
Conclusions: Telomere length was decreased in children with CHH. We found no correlation between RTL41
and clinical or laboratory parameters.42
43
44
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3INTRODUCTION49
50
Telomeres constitute the protective end-parts of human chromosomes and can contribute to the51
pathogenesis of aging and cancer. The phenotype of inherited telomere disorders includes bone marrow52
failure, malignancies, pulmonary fibrosis, liver cirrhosis, diabetes, and cardiovascular and gastrointestinal53
diseases [1]. Telomeres shorten with every cell division, but the loss can be compensated by telomerase-54
mediated elongation. The telomerase ribonucleoprotein complex consists of an RNA template, a catalytic55
reverse transcriptase subunit (TERT) and associated proteins that affect assembly, stability and recruitment of56
telomerase to telomeres (e.g. DKC, NOP10, NHP2, and GAR).  In addition to telomere elongation,57
telomerase has also been associated with regulation of a number of cellular functions including survival,58
inflammation, apoptosis, transcription and metabolism [2].59
Cartilage-hair hypoplasia (CHH, MIM #250250) is a rare autosomal recessive metaphyseal60
chondrodysplasia caused by biallelic mutations in the RMRP (RNA component of mitochondrial RNA61
processing endoribonuclease) gene [3]. The disease is over-represented in the Amish and Finnish populations62
[4,5]. Clinical features include severe disproportionate short stature, hair hypoplasia, variable63
immunodeficiency, anemia and increased risk of malignancies. Genotype-phenotype correlations are64
inconsistent and clinical manifestations vary even between siblings [6]. Mutation carriers remain65
asymptomatic [5,7].66
Complex pathogenesis of CHH involves cell cycle impairment and altered regulation of genes67
associated with cell proliferation and differentiation [8,9]. In addition, formation of a ribonucleoprotein68
complex by RMRP and TERT has been confirmed [10]. This complex produces double-stranded RNAs and69
regulates RMRP expression.70
Disorders of telomere maintenance, like dyskeratosis congenita (DC), share some clinical features71
with CHH, e.g. growth retardation, bone marrow failure leading to anemia and immunodeficiency, and72
increased incidence of malignancies [11]. Pulmonary fibrosis has also been linked to TERT mutations, both73
in idiopathic cases and in patients with DC [12]. Interestingly, we have recently reported fibrosis-like74
changes on high-resolution computed tomography of the lungs in patients with CHH [13].75
Despite the known association between RMRP and TERT, it remains unknown whether RMRP76
4mutations have a significant impact on the telomere elongating functions of telomerase. In order to further77
elucidate the pleiotropic consequences of RMRP mutations and the pathogenesis of CHH we evaluated78
relative telomere lengths (RTL) in a large cohort of Finnish children and adults with CHH, their first-degree79
relatives most of whom were heterozygous mutation carriers, and healthy controls. We also analyzed the80
correlation of RTL with the patients’ clinical and laboratory features.81
82
5METHODS83
84
Patients with genetically confirmed CHH were identified from the Finnish Chondrodysplasia85
Register and recruited to a study exploring clinical, genetic and immunological characteristics of CHH. Their86
first-degree relatives were contacted via the index persons. All individuals who agreed to participate, or their87
guardians, signed an informed consent. The study was approved by the Research Ethics Committee at88
Helsinki University Hospital, Finland.89
Clinical and laboratory data were retrieved retrospectively from the patient hospital records, as well90
as prospectively during study visits. Apart from CHH-related clinical features we evaluated also factors that91
could theoretically influence telomere length, such as smoking, obesity (body mass index Z-score) and92
hormone or immunosuppressive therapy. We also selected clinical features that could emerge from telomere93
impairment (immunodeficiency, malignancies, short stature), as well as the need for repeated blood94
transfusions and immunoglobulin replacement therapy. Since growth failure in CHH is progressive, we used95
age- and sex-specific growth data for CHH [14] to classify patients as having mild, moderate or severe96
growth failure, as described previously [15]. In the majority of patients, blood samples were drawn97
simultaneously for telomere measurement and for analysis of immunologic parameters characterizing the98
degree of bone marrow deficiency and/or immunodeficiency: hemoglobin, red blood cells, leukocytes,99
neutrophils, lymphocytes, CD3+, CD4+, CD8+, CD19+, CD16/56+ cell counts, immunoglobulin A, M and100
G levels, as well as Epstein-Barr virus (EBV) viral load and antibodies.101
Control group. First-degree relatives of the patients (n=86), all without features of CHH, included102
37 parents, 38 siblings and 11 children. Altogether, 74 of them were confirmed to be heterozygous RMRP103
mutation carriers while 12 were negative for RMRP mutations. The control group consisted of RMRP104
mutation-negative individuals: 1) siblings of the patients (n=12) and 2) individuals who had participated in105
our previous studies involving healthy children and adults (n=94). The data available on controls included106
age, sex, ethnic background (all of Finnish origin) and overall health (all healthy). Parts of the statistical107
analyses were performed in a case-control setting, and age- and sex-matched controls were selected from the108
control group for each patient or mutation carrier aiming at age difference of no more than 12 months.109
DNA extraction and RMRP sequencing. Peripheral blood samples were collected for all study110
participants. DNA was extracted with 5 Prime Archive Pure DNA Blood kit according manufacturer’s111
6instructions (5 Prime GmbH, Hilden; Germany). All samples were sequenced for RMRP to confirm the112
genotype in patients with CHH and to confirm or exclude heterozygous mutations in the patients’ unaffected113
relatives and the healthy controls. For patients and their relatives, blood samples were collected114
prospectively, whereas readily available DNA (extracted with the same methods) was used for healthy115
controls. Primers for RMRP (GRCh37/hg19) were designed with Primer3 v.0.4.0116
(http://frodo.wi.mit.edu/primer3/) for the gene, with a minimum of 60 bases of flanking regions adjacent to117
the coding region. PCR amplification was performed with DreamTaq (ThermoScientific, Waltham, MA,118
USA). The DNA fragments were then visualized with Midon Green Advanced DNA Stain (NIPPON119
Genetics, GmbH, Europe) on a 1.2% agarose gel, purified with ExoSAP (USB, Cleveland, OH, USA) and120
labeled with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). After bidirectional121
sequencing with an ABI3730 sequencer (Applied Biosystems), chromatograms were analyzed with122
Sequencher v5.0 (Gene Codes Corporation, Ann Arbor, MI, USA) using genomic NG_017041.1 and RNA123
reference sequence NR_003051.3. Primer sequences and detailed PCR protocols are available upon request.124
Telomere length measurement. Telomere length was determined by the quantitative-PCR method125
described by Cawthon [16], with minor modifications [17]. Briefly, sample DNA was analyzed in triplicate126
wells in a separate Telomere (TEL) and a single copy gene (HBG) reaction on the ABI7900HT instrument127
(Applied Biosystems), at two separate times. TEL/HBG (T/S) values were calculated by the 2−ΔCt method,128
where ΔCt = average CtTEL-average CtHBG. RTL were generated by dividing samples T/S value with the129
T/S value of a reference CCRF-CEM cell line DNA included in all runs.130
Statistical analysis. Subject’s age on the day of blood sampling was used for the analyses. To131
evaluate RTL correlations, we classified individuals to categories of short, average or long RTL for age and132
used both, RTL itself and RTL category, in the analysis. These categories were determined based on RTL and133
age data from the healthy controls. Individuals with RTL > 0.5 standard deviation (SD) from the regression134
line for age vs RTL were classified as having long RTL, those with RTL < -0.5 SD as having short RTL, and135
the remaining as having average RTL (Supplementary Figure 1). We applied the Mann-Whitney test for136
categorical and the Spearman's coefficient (rho) for continuous variables. Linear or logistic regression137
analysis was used for multivariate models. A p value <0.05 was considered significant. Statistical analyses138
were performed with the IBM SPSS software.139
7RESULTS140
141
Patient characteristics. Altogether, 48 Finnish patients (31 females, 17 males) with CHH142
participated in the study. Their median age was 38.2 years (range 6.0-70.8 years). Sanger sequencing of the143
RMRP gene showed that most of the patients (75%, 36/48) were homozygous for the g.70A>G mutation144
(rs199476103, now referred to as g.71A>G) while 12 patients (25%) were compound heterozygous for145
g.70A>G and either g.262G>T mutation (rs727502774, now referred to as g.263G>T) (n=11) or a 10-146
nucleotide duplication at position -13 (TACTCTGTGA, rs727502775) (n=1).147
Tables 1 and 2 present patients’ clinical and laboratory data. Nine patients had been diagnosed with148
malignancies, including basal cell carcinoma (n=6), B-cell lymphoma (n=2), uterus carcinoma (n=1) and149
vocal cord carcinoma (n=1). In the two patients who had survived lymphoma, no data were available on150
EBV status in lymphoma samples. No EBV-associated diseases were reported in our patients. Blood EBV151
viral load was undetectable by PCR in 10 individuals and 34/41 (83%) patients tested positive for serum152
antibodies to EBV. Two patients had required repeated red blood cell transfusions for anemia and another153
four patients had been treated with immunoglobulin replacement therapy. Some individuals reported history154
of smoking (n=9), intake of inhaled corticosteroids for physician-diagnosed asthma (n=15) or growth155
hormone treatment in childhood (n=3).156
157
8Table 1. Clinical features of 47 study subjects with cartilage-hair hypoplasia.158
Clinical feature Number of patients Proportion of patients
Growth deficiency
 Severe 3/47 6%
Moderate 17/47 36%
Mild 27/47 58%
History of
 Pneumonia 10/47 19%
Rhinosinusitis 27/47 57%
Otitis media 34/47 72%
Warts 15/47 32%
Hospitalization for varicella 5/34 15%
Smoking 9/47 19%
Normal susceptibility to infections* 15/47 32%
Combined immunodeficiency** 25/47 53%
History of
 Malignancies 9/47 19%
Repeated blood transfusions 2/47 4%
Immunoglobulin therapy 4/47 8%
Immunosuppressive therapy 2/47 4%
Growth hormone treatment 3/47 6%
Therapy with inhaled glucocorticoids 15/47 32%
Bronchiectasis 8/30 27%
Fibrosis-like lung changes 5/30 17%
159
* Normal susceptibility to infections was defined as occasional uncomplicated RTI or otitis media/rhinosinusitis not160
requiring surgical interventions, absence of pneumonias and sepsis and varicella not requiring hospitalization.161
** Patients with warts, recurrent HSV infections, varicella requiring hospitalization or malignancy were considered to162
have combined immunodeficiency.163
164
165
Table 2. Laboratory characteristics of study subjects with cartilage-hair hypoplasia. Cell counts are166
shown in cells x109/l with the exception of red blood cells (x1012/l). Hemoglobin and immunoglobulin levels are in g/l.167
Normal values in adults represent local laboratory reference values.168
169
Laboratory parameter Normal
values in
adults
Patients
tested (n)
Results, median
(range)
Patients with
decreased
counts/levels, n (%)
Red blood cells F 3.90-5.20,
M 4.25-5.70
47 4.32 (2.69-5.34) 5 (11%)
Hemoglobin F 117-155,
M 134-167
47 136 (102-161) 3 (6%)
White blood cells 3.4-8.2 47 6.0 (1.2-12.0) 4 (9%)
Absolute neutrophil count 1.5-6.7 47 1.76 (0.28-8.40) 3 (6%)
Absolute lymphocyte count 1.3-3.6 47 1.31 (0.26-3.25) 26 (55%)
CD3+ cells 0.85-2.28 46 0.93 (0.16-3.01) 19 (41%)
CD4+ cells 0.458-1.406 46 0.548 (0.118-1.312) 17 (37%)
CD8+ cells 0.24-0.98 46 0.30 (0.04-1.72) 19 (41%)
CD19+ cells 0.12-0.43 46 0.12 (0.00-0.34) 30 (65%)
CD16/56+ cells 0.08-0.57 46 0.18 (0.05-0.55) 3 (7%)
Immunoglobulin A 0.52-4.84 45 1.9 (0.4-7.5) 4 (9%)
Immunoglobulin M 0.36-2.84 46 0.9 (0.2-3.1) 4 (9%)
Immunoglobulin G 6.8-15.0 44 10.7 (4.2-15.7) 1 (2%)
170
F females, M males, n number171
9172
173
Telomere length. RTL measurement was performed by quantitative PCR on altogether 228 samples174
from patients (n=48), first-degree relatives (n=86) and healthy unrelated controls (n=94). Sanger sequencing175
detected 74 carriers for RMRP mutations among the CHH patients’ unaffected relatives (86%). Table 3176
demonstrates the characteristics of the participants according to the RMRP mutation status. There was a177
significant negative correlation between RTL and age in mutation carriers (rho -0.482, p<0.001) and non-178
carriers (rho -0.498, p<0.001), but not in patients (rho -0.236, p=0.107) (Figure 1). RTL was not influenced179
by sex in any age group.180
181
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Table 3. Characteristics of patients with cartilage-hair hypoplasia, asymptomatic RMRP mutation182
carriers and non-carriers.183
184
Patients with CHH RMRP mutation carriers Mutation-negative individuals
Size of group (n) 48 74 106
Sex, F/M (%) 31/17 (65%/35%) 39/35 (53%/47%) 64/42 (60%/40%)
Median age, years 38.2 (6.0-70.8) 48.8 (5.0-70.8) 37.1 (6.0-70.8)
Number of subjects aged:
5.0-18.0 years 9 (19%) 17 (23%) 19 (18%)
18.1-40.0 years 17 (35%) 12 (16%) 40 (38%)
40.1-70.8 years 22 (46%) 45 (61%) 47 (44%)
Mutation type (n, %): n/a
homozygote, g.70A>G 36 (75%) none
compound heterozygote 12 (25%) none
heterozygote, g.70>G none 58 (78%)
heterozygote, other* none 16 (22%)
Relation to patients (n, %): n/a
parents 37 (50%) none
siblings 26 (35%) 12 (11%)
children 11 (15%) none
unrelated none 94 (89%)
185
CHH cartilage-hair hypoplasia, F female, M male, n number of subjects, n/a not applicable, RMRP RNA component of186
mitochondrial RNA processing endoribonuclease187
* other mutations included g.262G>T or a 10-nucleotide duplication at position -13 (TACTCTGTGA).188
189
190
RTL in patients and mutation carriers. The proportion of CHH patients with short RTL for age191
was significantly higher (52%, 25/48) than among mutation carriers (20%, 15/74, p<0.001) or healthy non-192
carriers (29%, 31/106, p=0.011) (Table 4). In the sub-analysis by age group, almost all children with CHH193
had short telomeres for age (89%, 8/9). Further, two thirds of patients aged 18.1-40.0 years (65%, 11/17) and194
one fourth of those aged over 40.1 years (27%, 6/22) had short telomeres. Compared with RMRP mutation-195
negative individuals, the proportion of patients with short RTL was significantly higher in children (p=0.016)196
and adults up to 40.0 years of age (p=0.047), but not in older individuals (p=0.769) (Table 4).197
198
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Table 4. Relative telomere length as median (range) and as short, average or long for age in various199
age groups of patients with cartilage-hair hypoplasia, RMRP mutation carriers and non-carriers.200
Higher proportion of patients demonstrated RTL short for age (bold) compared with mutation carriers (p<0.001) or201
healthy non-carriers (p=0.011). Compared with RMRP mutation-negative individuals, the proportion of patients with202
short RTL was significantly higher in children (p=0.016) and adults up to 40.0 years of age (p=0.047), but not in older203
individuals (p=0.769).204
205
Study
group
Age group
(years)
Number of
subjects
Median RTL
(range)
Subjects with
short RTL, n (%)
Subjects with
average RTL, n (%)
Subjects with
long RTL, n (%)
Patients All ages 48 1.07 (0.70-1.81) 25 (52%) 11 (23%) 12 (25%)
6.0-18.0 9 1.12 (0.88-1.31) 8 (89%) 1 (11%) 0 (0%)
18.1-40.0 17 1.08 (0.91-1.72) 11 (65%) 2 (11.5%) 4 (23.5%)
40.1-70.8 22 1.06 (0.70-1.81) 6 (27%) 8 (36.5%) 8 (36.5%)
RMRP
mutation
carriers
All ages 74 1.16 (0.88-1.78) 15 (20%) 32 (43%) 27 (37%)
5.0-18.0 17 1.30 (0.95-1.77) 7 (41%) 6 (35%) 4 (24%)
18.1-40.0 12 1.20 (0.99-1.78) 3 (25%) 5 (42%) 4 (33%)
40.1-70.8 45 1.09 (0.88-1.45) 5 (11%) 21 (47%) 19 (42%)
RMRP
mutation-
negative
subjects
All ages 106 1.16 (0.71-2.05) 31 (29%) 45 (43%) 30 (28%)
6.0-18.0 19 1.25 (0.86-2.05) 7 (37%) 5 (26%) 7 (37%)
18.1-40.0 40 1.22 (0.88-1.78) 14 (35%) 17 (43%) 9 (22%)
40.1-70.8 47 1.07 (0.71-1.45) 11 (23%) 22 (47%) 14 (30%)
206
n number, RMRP RNA component of mitochondrial RNA processing endoribonuclease, RTL relative telomere length.207
208
209
We were able to find from the control group age- and sex-matched controls with no RMRP mutations210
for 40 patients (12 males, 28 females, median age 37.5 years) for case-control analyses. RTL was211
significantly shorter in patients (median RTL 1.05) compared with the controls (median RTL 1.21, p=0.017).212
Children aged ≤18 years accounted for this difference in RTL (median 1.09 in patients vs 1.25 in controls,213
p=0.015, n=8 pairs), while only a trend for shorter RTL was observed in those aged >18 and ≤40 years214
(median 1.07 vs 1.26 in controls, p=0.069, n=14 pairs) and no difference was detected in the age group >40215
years (median RTL 1.03 vs 1.08 in controls, p=0.443, n=18 pairs) (Figure 2).216
When all study samples were included in analyses, a significant difference in RTL between patients217
with CHH and healthy subjects (including RMRP mutation carriers and non-carriers) was also observed in218
children (6.0-18.0 years of age, median RTL 1.12 in nine patients vs 1.26 in 36 controls, p=0.008) (Figure 3).219
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No significant difference was detected in the older age-groups, although young adults with CHH220
demonstrated a tendency for shorter telomeres (median RTL 1.08 in 17 patients vs 1.22 in 52 controls,221
p=0.082).222
We compared RTL in 48 RMRP mutation carriers with age- and sex-matched non-carrier controls,223
and observed no difference in the median RTL between these two groups (1.16 vs 1.10, p=0.224) (data not224
shown).225
RTL and CHH-related characteristics and morbidity. In the patient cohort, RTL and classified226
RTL (short, average or long for age) showed no correlation with the type of RMRP mutation, sex, history of227
blood transfusions, immunoglobulin substitution, hormone or immunosuppressive therapy, obesity or history228
of smoking. Various infectious manifestations separately or in combinations, fibrosis-like lung changes,229
history of malignancies, the severity of growth failure and analyzed laboratory parameters did not correlate230
with RTL itself or RTL category (Supplementary Table 1). In two patients who had survived lymphoma, RTL231
was average and long for age respectively.232
13
DISCUSSION233
234
Our study demonstrates shorter telomeres in DNA from peripheral blood in children with CHH. The235
interpretation of our findings necessitates further studies to determine whether shorter telomeres are the236
cause or the consequence in CHH pathology. Decreased telomere length may reflect the increased number of237
cell divisions required to compensate for the impaired cell cycle and increased apoptosis reported in CHH238
[18]. Alternatively, telomerase defects can represent primary pathologic mechanism contributing to stem cell239
exhaustion, including bone marrow failure present in some patients with CHH. Our findings confirm the240
significance of RMRP in telomerase function.241
RTL correlated significantly with age in RMRP mutation carriers and non-carriers, but not in patients242
with CHH, which can be explained by shorter telomeres in pediatric patients. Individuals with CHH have243
increased mortality in childhood and young adulthood from infections and malignancies [19,20]. A high244
proportion of our patients (46%, 22/48) were over 40 years of age and thus represent a selected population of245
less affected patients who escaped fatal complications in early life. Therefore, normal telomere length in246
adults with CHH can indicate a survival advantage. The absence of correlations between telomere length and247
clinical and laboratory characteristics can derive from the small sample size. Also, RTL is a rough estimate of248
telomere structure and represents only a part of the complex telomere biology.249
Interestingly, some DC mutation carriers demonstrate telomere shortening while remaining250
asymptomatic and inheritance of shorter telomeres probably induces more severe disease in subsequent251
generations [21]. The finding of normal telomeres in RMRP mutation carriers contradicts the data from252
families with DC. More research is needed to test pedigrees where CHH has been diagnosed in more than253
one generation. If the shorter telomere length is indeed inherited, this may result in more severe disease in254
the affected offspring of patients with CHH in future generations.255
Cell immortalization and subsequent development of cancer can emerge from abnormal telomere256
maintenance [22]. While DC and CHH are both characterized by increased risk of malignancies, the types of257
tumors developing in patients with these disorders differ. The most common malignancies in individuals with258
DC include head and neck squamous cell carcinomas, while in subjects with CHH, non-Hodgkin lymphomas259
and basal cell carcinomas predominate [20,23]. Accordingly, in the light of present data, immunodeficiency260
14
rather than the telomere length is the nominator in predisposition to malignancy in CHH patients.261
Immunodeficiency in patients with CHH may predispose them to EBV-associated lymphoproliferative262
disorders. Unfortunately, no data were available on EBV status in lymphoma samples from the two patients263
in our cohort. The majority of our patients had detectable serum antibodies to EBV but EBV DNA was not264
detected by PCR in peripheral blood. EBV causes telomere dysfunction in the infected cells [24, 25] and it is265
possible that this is relevant in CHH. Therefore, further research on alteration in telomere functions and the266
role of EBV in CHH patients with malignancies would be warranted.267
The results of our study have important clinical implications. Patients with CHH can require268
hematopoietic stem cell transplantation and defective telomere biology should be taken into account when269
choosing conditioning regimen. Also, bone marrow failure in patients with DC has been successfully treated270
with androgens (probably due to telomerase up-regulation) and this treatment option may be considered in271
selected patients with CHH [26-28]. Furthermore, telomere length measurement may guide diagnostic272
process in individuals with immunodeficiency of unknown etiology and CHH should be included in the273
differential diagnosis of children with short telomeres.274
We recognize strengths and limitations in our study. This is the first study to evaluate telomere length275
in patients with CHH. The high prevalence of the disease in our population provided us with a unique276
opportunity to recruit a large cohort of patients and their unaffected relatives with a homogenous genetic and277
ethnic background and with a wide age range; in rare diseases such an approach is seldom possible. The278
drawbacks of our study include insufficient clinical data from relatives of patients with CHH and healthy279
controls. Thus, it was impossible to analyze the influence of e.g. smoking or medications on RTL. However,280
in the patient group, these factors did not affect telomere length and none of the patients aged <18 years281
reported smoking. The number of healthy controls was rather small, which increases the risk of bias and due282
to the inter-individual variability of telomere length our data may not be applicable to particular individuals283
with CHH. Also, no data were available on metabolic profile (glucose, insulin and lipid profile, blood284
pressure) of our patients, hindering the evaluation of its relationship with RTL. Another limitation is the use285
of RTL, where mean telomere length of all chromosome ends is estimated. Telomere length distributions and286
critically short individual telomere ends cannot be detected by this method.287
Our results suggest that telomere length is abnormal in children with CHH. Further studies are288
required to explore functional consequences of altered telomere maintenance and possible clinical289
15
implications of these findings. Longitudinal follow-up of patients with CHH is necessary to establish the290
significance of telomere length as a predictor of disease severity and mortality.291
292
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LEGENDS TO FIGURES417
418
Figure 1. Correlation of relative telomere length with age in 228 samples from patients with cartilage-hair 419
hypoplasia, their relatives and healthy controls. Every dot corresponds to a measurement from a single 420
individual. RTL correlated significantly with age in RMRP mutation carriers (rho -0.482, p<0.001) and non-421
carriers (rho -0.498, p<0.001), but not in patients (rho -0.236, p=0.107).422
423
424
Figure 2. Comparison of relative telomere length (RTL) in a case-control setting in 40 patients with 425
cartilage-hair hypoplasia (median RTL 1.05) and 40 age- and gender-matched healthy controls negative for 426
RMRP mutation (median RTL 1.21, p=0.017). RTL was significantly shorter in children with CHH (median 427
1.09 vs 1.25 in controls, p=0.015, n=8 pairs). Adults with CHH showed a trend for shorter RTL in the age 428
group >18 and ≤40 years (median 1.07 vs 1.26 in controls, p=0.069, n=14 pairs), while no difference was 429
detected in the age group >40 years (median RTL 1.03 vs 1.08 in controls, p=0.443, n=18 pairs).430
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431
432
Figure 3. Comparison of relative telomere length (RTL) in different age groups of patients with cartilage-hair 433
hypoplasia (CHH), RMRP mutation carriers and non-carriers. Children with CHH (aged ≤18 years) 434
demonstrate significantly shorter RTL compared with asymptomatic mutation carriers and non-carriers. No 435
difference in RTL was observed in young adults (aged >18 and ≤40 years) or adults (aged >40 years) with 436
CHH compared with controls.437
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ABBREVIATIONS440
441
CHH, cartilage-hair hypoplasia442
DC, dyskeratosis congenita443
EBV Epstein-Barr virus444
rho, Spearman's correlation coefficient445
RMRP, RNA component of mitochondrial RNA processing endoribonuclease446
RTL, relative telomere length447
SD standard deviation448
TERT, telomerase reverse transcriptase449
